Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 4
2011 2
2012 3
2013 6
2014 2
2015 4
2016 2
2018 1
2019 2
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed for Bookshelf ID: 4854322

24 results

Results by year

Filters applied: . Clear all
Page 1
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Shantakumar S, Nordstrom BL, Djousse L, Hall SA, Gagnon DR, Fraeman KH, van Herk-Sukel M, Chagin K, Nelson J. Shantakumar S, et al. Cancer Chemother Pharmacol. 2016 Sep;78(3):559-66. doi: 10.1007/s00280-016-3112-9. Epub 2016 Jul 20. Cancer Chemother Pharmacol. 2016. PMID: 27438066 Free PMC article.
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, Briley LP, Mitrica I, Spraggs CF, Nelson MR, Tada H, du Bois A, Powles T, Kaplowitz N, Pandite LN. Xu CF, et al. Clin Cancer Res. 2016 Mar 15;22(6):1371-7. doi: 10.1158/1078-0432.CCR-15-2044. Epub 2015 Nov 6. Clin Cancer Res. 2016. PMID: 26546620 Free PMC article.
Hepatotoxicity of molecular targeted therapy.
Karczmarek-Borowska B, Sałek-Zań A. Karczmarek-Borowska B, et al. Contemp Oncol (Pozn). 2015;19(2):87-92. doi: 10.5114/wo.2014.43495. Epub 2014 Aug 29. Contemp Oncol (Pozn). 2015. PMID: 26034384 Free PMC article. Review.
Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P, Carpenter C, Pandite L, Kaplowitz N. Powles T, et al. Eur J Cancer. 2015 Jul;51(10):1293-302. doi: 10.1016/j.ejca.2015.03.019. Epub 2015 Apr 17. Eur J Cancer. 2015. PMID: 25899987 Free PMC article. Review.
Promising management of pazopanib-induced liver toxicity.
Vlenterie M, van Erp NP, van der Graaf WT. Vlenterie M, et al. Acta Oncol. 2015 Jul;54(7):1064-6. doi: 10.3109/0284186X.2015.1004368. Epub 2015 Mar 3. Acta Oncol. 2015. PMID: 25734660 No abstract available.
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Karlin N, Sideras K, Morris JC 3rd, McIver B, Hay I, Fatourechi V, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Cher Goh B, Isham CR, Harris P, Erlichman C; Endocrine Malignancies Disease Oriented Group, Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium. Bible KC, et al. J Clin Endocrinol Metab. 2014 May;99(5):1687-93. doi: 10.1210/jc.2013-3713. Epub 2014 Feb 25. J Clin Endocrinol Metab. 2014. PMID: 24606083 Free PMC article. Clinical Trial.
24 results